Gene therapy has shown transformative potential towards a number of previously untreatable clinical conditions, using highly innovative approaches including autologous personalized therapies. Manufacturing challenges and limited production capabilities, however, result in a high cost of goods for clinical and commercial materials, which in turn, create real clinical, affordability and patient access issues. The need for genuinely innovative manufacturing process to address these challenges will be discussed.
Tony has over 30 years of experience in the large-scale manufacture of biopharmaceuticals. As a founding staff member of Cobra Tony has been responsible for the development of much of Cobra’s manufacturing technologies in the field of DNA and virus production. He has held a number of senior roles, managing both manufacturing and development functions within the company, working on over 40 programmes for the development of novel therapeutic products including protein, recombinant virus, bacteriophage and plasmid DNA products. His current role is based in the commercial group supporting external collaboration and outreach activities.
Additionally, Tony is currently a member of the steering committee of BioProNET, the BIA Science and Innovation Advisory Committee (SIAC), and serves on EPSRC, BBSRC and Vinnova review panels. He was also named in the Medicine Makers 2019 Power list as one of the industries’ top influencers. He has also served as a member of the BBSRC BSI (Biosciences for industry panel), the steering committee of the UK Bioprocess Research Industry Club (BRIC), the scientific advisory of the Pharmaceutical Centre for Excellence (COEBP) at the University of Manchester, the Executive Board of the European Federation of Biotechnology and the industrial advisory board for the Astbury Centre at the University of Leeds.